Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats.

Abstract

We investigated the effects of T-1095 (3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-(6-O-methoxycarbonyl)-beta-D-glucopyranoside), an orally active inhibitor of Na+-glucose cotransporter, on hyperglycemia and insulin resistance in skeletal muscle of streptozotocin (STZ)-induced diabetic rats. Chronic (4 weeks) administration of T-1095 as food admixture (0.01 -0.1% wt/wt) suppressed the blood glucose level without affecting the food intake and body weight. In addition, the reduced 2-deoxyglucose uptake and lactate release in the soleus muscle of STZ rat was ameliorated by chronic treatment of T-1095. These data suggest that T-1095 improves insulin sensitivity in skeletal muscle through correction of hyperglycemia and has novel therapeutic potential for treatment of diabetes mellitus through removing glucose toxicity.

• Authors: A Oku, K Ueta, K Arakawa, T Kano-Ishihara, T Matsumoto, T Adachi, K Yasuda, K Tsuda, K Ikezawa, A Saito
• Journal: Japanese journal of pharmacology (Jpn J Pharmacol) Vol. 84 Issue 3 Pg. 351-4 (Nov 2000) ISSN: 0021-5198 [Print] Japan
• PMID: 11138738 (Publication Type: Journal Article)

Chemical References

• Carbonates
• Glucosides
• Hypoglycemic Agents
• Monosaccharide Transport Proteins
• T 1095
• Lactic Acid
• Deoxyglucose

Topics

• Animals
• Carbonates (therapeutic use)
• Deoxyglucose (metabolism)
• Diabetes Mellitus, Experimental (drug therapy)
• Glucosides (therapeutic use)
• Hyperglycemia (drug therapy)
• Hypoglycemic Agents (therapeutic use)
• In Vitro Techniques
• Insulin Resistance
• Lactic Acid (metabolism)
• Male
• Monosaccharide Transport Proteins (antagonists & inhibitors)
• Muscle, Skeletal (metabolism)
• Rats